Definium Therapeutics, Inc. (DFTX)
Valuation Overview•Is Definium Therapeutics, Inc. Overvalued or Undervalued?
The market is pricing the stock in line with historical averages, assuming steady-state growth.
Underlying fundamental quality and solvency metrics are in stable range.
Analysts remain cautious, with consensus price targets indicating limited room for upside expansion.
Confirm your valuation thesis with live pattern overlays, key pivot levels, and AI trade plans.
Verdict: Highly distressed profile flashing severe fundamental warning signs.
Wall Street is cautious, forecasting potential downside. The company currently retains all capital for reinvestment and growth rather than returning it to shareholders.
DFTX demonstrates adequate business quality with stable profitability. This is backed by a fortress balance sheet, holding significant net cash ($258M) and minimal debt risk.
The company maintains stable top-line performance paired with stable bottom-line earnings.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | — | — | — | — | |
| EBITDA | -$157.8M | — | -41.3% | — | — | |
| Net Income | -$159.0M | -69.1% | -47.9% | — | -113.7% | |
| EPS (Diluted) | $-1.44 | -1273.3% | — | — | -5.8% | |
| Free Cash Flow | -$52.8M | -66.3% | -37.9% | -41.0% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | — | — | — | — |
| Operating Margin | — | — | — | — |
| Net Margin | — | — | — | — |
| FCF Margin | — | — | — | — |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q1'26Latest | $-0.48 | $-0.51 | -6.3% | ||
| Q4'25 | $-0.52 | $-0.78 | -50.0% | ||
| Q3'25 | $-0.38 | $-0.50 | -31.6% | ||
| Q2'25 | $-0.36 | $-0.35 | +2.8% | ||
| Q1'25 | $-0.33 | $-0.41 | -24.2% | ||
| Q4'24 | $-0.28 | $-0.27 | +3.6% | ||
| Q3'24 | $-0.30 | $-0.48 | -60.0% | ||
| Q2'24 | $-0.66 | $-1.14 | -72.7% |
The S&P 500 is at 29.9x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Definium Therapeutics, Inc. (DFTX) valuation, health, and returns.
Definium Therapeutics, Inc. valuation is being assessed using available models.
Definium Therapeutics, Inc. has multiple valuation anchors: Wall Street Analyst Target: $20.00 (implying -53.3% upside). A convergence of these signals offers higher conviction.
Definium Therapeutics, Inc. displays n/a financial health with a composite quality score of N/A/100, supported by a Piotroski F-Score of 3/9, Return on Invested Capital (ROIC) of -389.5%.
Definium Therapeutics, Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Definium Therapeutics, Inc.'s current growth trajectory is Stable. The company achieved N/A 1Y revenue growth and -1273.3% 1Y EPS growth, compared to its 3Y revenue CAGR of N/A.
Wall Street consensus is Buy based on 1 analysts. The consensus price target represents a -53.3% change from current levels.
No major financial distress warning signs or extreme volatility triggers are flagged at this time.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.